Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
ConditionMSI-H/dMMR Solid Tumors
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeiGene
About this trial
In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).
Eligibility criteria
Qualifiers
Having histological confirmed diagnosis of malignancy
Having locally advanced unresectable or metastatic solid tumors with MSI-H or dMMR
Having received prior cancer therapy regimen(s) for advanced disease.
At least 1 measurable lesion as defined per RECIST Version (v) 1.1
Disqualifiers
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Active leptomeningeal disease or uncontrolled brain metastasis.
Clinically significant pleural effusion, pericardial effusion or ascites
Active autoimmune diseases or history of autoimmune diseases that may relapse
Trial design
Treatments tested in this trial
- Tislelizumab (BGB-A317)
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov